pharma segment uphold revenu growth
downgrad rate hold maintain tp
give upsid potenti
deriv estim base
forward price-to-earnings multipl ep
expect top-lin growth
optimist perform per
expect recommend hold rate upsid
potenti less rise price
estim base follow factor strong
perform segment continu growth
medic devic segment new product launch
quarter acquisit made strengthen
johnson johnson strong quarterli result due
double-digit growth segment
continu growth medic devic segment
growth also due new product launch growth
market-lead product revenu increas
total revenu segment increas
growth due
strong growth stelara zytiga darzalex imbruvica
sustenna/xeplion/trinza/trevicta xarelto
total revenu medic devic segment increas
increas due
growth across busi except diabet
compani namejohnson johnsontickerjnjstock ratingholddowngradeindustri viewoverweightpositivepric aug week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth johnson johnson| august
incom statement
non-
per share item
balanc sheet item
product perform develop
valuat consensu perform
total revenu consum segment increas
off-set lower sale babi
adjust net earn increas
ep increas
compar adjust ep increas
compar
announc accept bind offer
platinum equiti acquir lifescan busi
also announc receipt bind offer
fortiv corpor acquir advanc steril
product busi
fda approv idesign refract studio part
next-gener lasik platform measur eye
insid enabl highli precis person vision
expect revenu grow organ rang
expect revenu
adjust ep expect
rang
current price-to-earnings averag price-to-earnings
price-to-earnings volatil past
trend ep price-to-earnings trade
price-to-earnings went
due stock momentum expect forward price-to-earnings
recommend hold rate stock price
increas quarter estim per
expect base jnj perform strong
growth pharma segment
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date sep ex-dividend date aug last split factor new per last split date jun inform johnson johnson| august
incom statement
non-
per share item
balanc sheet item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement item total gross research develop sell gener administr sg oper depreciation- oper profit interest incom special interest incom minor interest- incom incom net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli johnson johnson| august
 market account receivable- total prepaid current assets- total current build machineri furnitur total fix non-curr defer incom non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom non-curr minor interest total non-curr total prefer stock equity- common stock addit paid-in capital- retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item johnson johnson| august
cash equival compar
market secur end flow oper
due net earn non-cash expens adjust
use invest activ cash due addit properti
plant equip net purchas invest market secur
acquisit
use financ activ cash use give dividend
sharehold net retir short term debt repurchas common
stock
depreciation- defer incom oper increas decreas increas decreas current assets- decreas increas payables- decreas increas current liabilities- decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant net invest financ activitiesissu issuanc capit stock- repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end johnson johnson| august
deliv strong quarterli result due double-digit growth
pharmaceut segment increas sale momentum medic devic
busi strong perform also led continu growth market-
lead product new launch
compar
jnj revenu increas compar
oper sale increas posit impact currenc
net impact acquisit divestitur
world-wide oper sale growth posit total revenu
 increas compar
total intern revenu increas compar
cog revenu
increas
compar
due
expens relat
sale compani europ grew includ
oper growth posit currenc impact sale
compani western hemispher exclud grew
includ oper growth neg currenc
impact
sale compani asia-pacif africa region grew
includ oper growth posit currenc
impact
cog increas compar
cog revenu increas compar
due higher amort expens relat actelion acquisit
gross margin sale compar sale
johnson johnson| august
sg expens increas compar
sg expens revenu declin
compar due lower cost rel sale growth
busi partial off-set new product launch
medic devic consum segment
 expens increas compar
 sale increas compar
increas due continu invest spend advanc
in-process research develop asset
investig drug treatment respiratori syncyti viru rsv
human metapneumoviru hmpv carri valu suspend
on-go phase trial later analysi inform
complet reassess carri valu in-process research
develop asset upon complet analysi develop timelin
significantli delay develop abandon may incur impair
interest expens compar
increas due higher averag interest rate partial off-set
lower averag debt balanc jnj debt posit juli
compar period year ago
expens declin compar
includ higher gain divestitur mainli nizor
lower cost relat actelion acquisit compar
period year ago
effect tax rate compar
adjust tax rate compar
adjust net earn increas compar
net earn increas
compar
sg expens
revenu declin
due
lower cost rel
sale growth
compar
net margin compar
net earn includ after-tax intang amort expens
charg after-tax special item
gaap ep increas compar
adjust ep increas compar
total revenu increas compar
currenc fluctuat posit impact
net impact acquisit divestitur world-wide oper
sale growth posit
revenu compani increas
compar total intern revenu increas
compar
sale compani europ grew compar
includ oper growth posit
currenc impact
sale compani western hemispher exclud grew
compar includ
oper growth partial off-set neg currenc
impact
sale compani asia-pacif africa region grew
compar includ oper
growth posit currenc impact
cog increas compar
cog sale increas compar
increas
compar
sale compani
asia-pacif africa
region grew
compar
increas cog due higher amort expens relat
actelion acquisit gross margin declin compar
sg expens increas compar
sg expens sale declin compar
compar
 expens increas compar
 expens sale increas compar
increas due continu invest spend
advanc product develop pipelin
gaap ep increas
compar
ep increas
compar
interest expens compar
increas due higher averag interest rate partial off-set
lower averag debt balanc jnj debt posit juli
compar period year ago
expens compar
month period includ higher gain divestitur mainli
nizor lower cost relat actelion acquisit
partial off-set higher litig expens compar prior-
effect tax rate compar
adjust tax rate compar
net earn increas compar
adjust net earn increas
compar net margin compar
gaap ep increas compar
adjust ep increas compar
divid major segment consum segment
medic devic segment contribut sale
consum segment contribut sale medic devic segment
contribut
total revenu
increas
due
over-the-count
tylenol analges
ogx dr ci labo
total revenu consum segment increas
compar consist oper
decreas posit impact currenc total revenu
increas compar
total revenu declin compar
total intern revenu increas
compar
consum segment revenu increas due over-the-count
product includ tylenol analges digest health product
intern beauti product primarili neutrogena ogx dr ci labo
partial off-set lower sale babi care product quarter
divestitur anti-dandruff shampoo brand nizor certain
ketoconazole-bas shampoo brand complet
world-wide revenu
increas
compar
world-wide revenu
declin
compar
world-wide revenu beauti product increas
compar total revenu increas
compar
total revenu declin
compar total intern revenu increas
compar
beauti franchis growth due new product launch strength
dr ci labo geograph expans partial off-set time
neutrogena aveeno suncar product season
world-wide revenu oral product declin
compar total revenu increas
compar compar
total revenu increas
compar total intern revenu declin
compar
oral product revenu decreas due declin intern
revenu partial off-set due market share growth new
world-wide revenu over-the-counter product increas
compar total revenu increas
compar
total revenu increas
compar total intern revenu increas
over-the-counter franchis growth due share growth across multipl
brand includ tylenol digest health product outsid
 strength children motrin anti-smok aid sale
recent acquisit rhinocort contribut growth
world-wide revenu babi product declin
compar total revenu declin
compar
total revenu decreas
compar total intern revenu decreas
compar
babi franchis revenu declin due retail stock reduct
discount anticip relaunch competit
pressur johnson
world-wide revenu women health product increas
compar total revenu increas
compar
world-wide revenu
compar
world-wide revenu
declin
compar
total revenu increas compar
total intern revenu increas
compar
world-wide revenu wound product decreas
compar total revenu decreas
compar
total revenu declin compar
total intern revenu declin
compar
wound care/oth franchis revenu declin due divestitur
compe
world-wide revenu pharmaceut segment increas
compar total revenu increas
compar
total revenu increas
compar total intern revenu increas
compar
sale includ impact actelion ltd contribut
world-wide oper sale growth growth due strong
growth stelara zytiga darzalex imbruvica tremfya
xarelto
pharmaceut
segment increas
compar
segment growth
due strong growth
stelara zytiga
xarelto
revenu increas
compar
increas
compar
world-wide immunolog revenu increas
compar total revenu increas
compar
total immunolog revenu increas
compar total intern revenu increas
compar
growth immunolog product due strong uptak stelara
crohn diseas immunolog market growth launch tremfya
strength across major region expand indic simponi
/simponi aria immunolog neg impact lower sale
remicad due increas discounts/reb biosimilar competit
simponi simponi aria revenu increas
compar total revenu increas
compar total revenu
increas total intern revenu
increas
stelara revenu increas compar
total revenu increas
compar total revenu increas
total intern revenu increas
remicad revenu declin compar
total revenu decreas
compar total revenu declin
revenu export declin
total intern revenu declin
patent remicad certain countri europ expir februari
biosimilar version remicad introduc certain
market outsid unit state result reduct sale
remicad market
world-wide revenu cardiovascular decreas
compar total revenu declin
compar
total cardiovascular revenu declin
compar total intern revenu increas
compar
declin due lower sale invokana /invokamet
 due increas price discount market share
declin due competit pressur declin partial off-set
sale growth xarelto due increas market share
xarelto revenu increas compar
total revenu increas
compar
cardiovascular
decreas
compar
increas
compar
invokana invokamet revenu decreas
compar total revenu declin
compar total revenu declin
total intern revenu increas
world-wide revenu oncolog increas
compar total revenu increas
compar
total oncolog revenu increas
compar total intern revenu increas
compar
contributor oncolog growth strong sale darzalex
imbruvica due increas patient uptak sale zytiga driven
latitud data market growth sale launch erleada
also contribut growth
darzalex revenu increas compar
total revenu increas
compar total revenu increas
total intern revenu
imbruvica revenu increas compar
total revenu increas
compar total revenu increas
total intern revenu increas
oncolog increas
compar
increas
compar
zytiga revenu increas compar
total revenu increas
compar
world-wide revenu increas compar
total revenu increas compar
total revenu compar
total intern revenu compar
pulmonari hypertens new therapeut area establish
acquisit actelion june
increas
compar
world-wide revenu
product increas
compar
opsumit revenu increas compar
total revenu total
intern revenu
tracleer revenu increas compar
total revenu total
intern revenu
uptravi revenu total revenu
total intern revenu
world-wide revenu infecti diseas product increas
compar total revenu increas
compar
total revenu declin compar
total intern revenu increas
compar
increas revenu due sale growth edurant/rilpivirin
prezcobix/rezolsta launch symtuza partial off-set
lower sale prezista
edur revenu increas compar
total revenu increas
compar total revenu declin
total intern revenu increas
prezista prezcobix rezolsta symtuza revenu increas
compar total revenu increas
compar total revenu
 declin slightli total intern
revenu increas
world-wide revenu neurosci product increas
compar total revenu increas
compar
total revenu increas
compar total intern revenu increas
compar
growth due strong sale invega sustenna/xeplion/trinza
/trevicta off-set cannib risperd consta
gener competit concerta /methylphenid
increas
compar
neurosci
product increas
compar
world-wide revenu neurosci product increas
compar total revenu increas
compar
total revenu increas
compar total intern revenu increas
compar
growth due strong sale invega sustenna/xeplion
/trinza /trevicta off-set cannib risperd
consta gener competit concerta /methylphenid
invega sustenna xeplion trinza trevicta revenu increas
compar total revenu
increas compar total
revenu increas total
intern revenu increas
concerta methylphenid revenu increas
compar total revenu decreas
compar total revenu
 decreas total intern revenu
increas
world-wide revenu medic devic segment increas
compar total revenu increas
compar
total revenu increas compar
total intern revenu increas
compar
neurosci
product increas
compar
medic devic
segment increas
compar
growth due acuvu contact lens surgic product
vision busi electrophysiolog product intervent solut
busi biosurg intern endocutt advanc surgeri
busi wound closur product gener surgeri busi trauma
product orthopaed busi partial off-set declin
diabet busi spine product orthopaed busi
world-wide revenu diabet product decreas
compar total revenu
decreas compar
lower sale due decis exit anima insulin pump
busi price declin competit pressur
total revenu increas
compar total intern revenu decreas
compar
world-wide revenu intervent solut increas
compar total revenu increas
compar
total revenu increas
compar total intern revenu increas
compar
diabet
product decreas
compar
intervent
solut increas
compar
increas revenu due strong oper growth
electrophysiolog busi grew due atrial fibril procedur
growth continu uptak thermocool smarttouch contact
world-wide revenu orthopaed decreas
compar total revenu decreas
compar
total revenu decreas
compar total intern revenu increas
compar
declin due codman neurosurgeri divestitur share loss
spine competit pressur knee partial off-set
growth hip sale growth trauma due continu uptak new
product primarili tfn-advanc nail system
total revenu hip product increas
compar total revenu
total intern revenu increas
total revenu trauma product increas
compar total revenu
total intern revenu increas
total revenu spine product declin
total revenu knee product declin
orthopaed
decreas
compar
total revenu
increas
compar
world-wide revenu surgic product increas
compar total revenu increas
compar
total revenu increas compar
total intern revenu increas
compar
advanc surgeri revenu increas
compar total revenu
total intern revenu increas
due biosurgeri product intern endocutt
gener surgeri revenu increas
compar total revenu increas
total intern revenu increas
increas due growth wound closur
total revenu vision care product increas
compar total revenu increas
total revenu increas
compar total intern revenu increas
compar
growth due market consumpt contact lens categori
saw growth astigmat daili dispos lens oasi
famili increas also due strong growth japan surgic growth
due cataract perform growth recent acquisit
surgic product
increas
compar
total revenu
increas
compar
increas
compar
contact lens revenu increas compar
total revenu increas
compar total intern
revenu increas compar
surgic revenu increas compar
total revenu total
intern revenu
acquisit
compani special
develop
immunotherapi
made follow develop acquisit
quarter fda approv addit indic darzalex
combin velcad proteasom inhibitor melphalan alkyl
agent prednison treatment patient newli diagnos
multipl myeloma inelig autolog stem cell transplant
european commiss grant market author juluca two-drug
regimen once-daili single-pil treatment
supplement new drug applic submit fda seek
expand indic opsumit includ treatment adult
inoper chronic thromboembol pulmonari hypertens improv
exercis capac pulmonari vascular resist
acquisit benevir biopharm inc privately-held
biopharmaceut compani special develop oncolyt
immunotherapi complet
world-wide collabor enter bristol-my squibb compani
develop commerci factor xia inhibitor includ
prevent treatment major thrombot condit
announc accept bind offer platinum equiti
acquir lifescan busi also announc receipt
bind offer corpor acquir advanc steril
product busi aggreg valu subject customari
accept
bind offer
platinum equiti
acquir lifescan
busi
fda approv idesign refract studio part next-gener lasik
platform measur eye insid enabl highli precis
juli acquisit asset medic enterpris distribut llc
privat held develop surgic impactor technolog includ
autom surgic impactor use hip replac
expect revenu
grow rang
improv bp
improv bp
revenu expect rang
effect tax rate expect rang
adjust ep expect rang
deliv strong quarterli result due double-digit growth
pharmaceut segment continu increas sale medic
devic segment revenu increas
strong perform quarter also due new product launch
 erleada continu increas market-lead product
double-digit growth
continu increas
sale medic
total revenu segment increas
due strong growth key product mainli stelara
zytiga darzalex imbruvica total revenu medic devic
segment increas increas due
growth across busi except diabet busi declin
quarter total revenu consum segment increas
partial off-set lower sale babi care product
announc accept bind offer platinum equiti
acquir lifescan busi also announc receipt bind
offer corpor acquir advanc steril product
busi aggreg valu fda approv idesign refract
studio part next-gener lasik platform measur eye insid
enabl highli precis person vision correct
ytd stock perform compar
roa roi roe ttm basi respect
focus invest innov posit compani deliv long-
term sustain growth
focus invest
innov
posit compani
deliv long-term
non- reconcili
non- reconcili
non- reconcili
incom statement
non-
per share item
balanc sheet item
product perform develop
valuat consensu perform
y/i revenu growth ttm compar
y/i ep growth ttm compar
gross margin declin ttm compar due increas cog
oper margin declin ttm compar due increas expens
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth johnson johnson| august
mrqgross mrqcog mrqoper mrqsg mrqnet mrqr sale johnson johnson| august
invest flow
mrqyoy growth revenu growthoper incom growthep mrqfinanci mrqreturn mrqreturn mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre /sale johnson johnson| august
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item johnson johnson| august
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant purchas sale business- purchas sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free johnson johnson| august
current price-to-earnings averag price-to-earnings price-to-earnings volatil past
trend ep price-to-earnings trade price-to-earnings went
due stock momentum expect forward price-to-earnings
incom statement
non-
per share item
balanc sheet item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdershar report outvaluevanguard group inc state mutual automobil insur northern trust america geod capit manag wellington manag compani massachusett servic top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard spdr etf vanguard institut fund-institut ishar fidel washington mutual investor select sector spdr fund-health vanguard -valu mf seri trust i-mf valu johnson johnson| august
developmentsjohnson johnson consum inc announc agreement acquir zarbe inc leader naturally-bas healthcar productsjohnson johnson consum inc announc enter definit agreement acquir zarbe inc privat held compani leader naturally-bas healthcar product acquisit includ full line zarbe natur product children adult financi term transact disclos janssen provid updat imbruvica ibrutinib phase phoenix trial newli diagnos non-germin center cell non-gcb subtyp diffus larg b-cell lymphoma dlbcl janssen pharmaceut compani johnson johnson announc top-line result phase phoenix trial evalu investig use imbruvica ibrutinib treatment newli diagnos non-germin center cell non-gcb subtyp diffus larg b-cell lymphoma dlbcl aggress form non-hodgkin lymphoma nhl studi compar imbruvica plu rituximab cyclophosphamid doxorubicin vincristin prednison r-chop versu r-chop current standard care dlbcl clinic trial meet primari endpoint event-fre surviv patient non-gcb subtyp dlbcl includ activ cell-lik subtyp dlbcl janssen conduct analys phoenix studi result assess potenti efficaci imbruvica observ patient sub-popul fda approv gener custom lasik treatment idesign refract studiojohnson johnson vision announc fda approv idesign refract studio make system use topography-integr wavefront-guid technolog allow doctor take precis measur eye insid deliv lasik procedur person individu patient approv myopia hyperopia mix astigmat addit avail lasik platform indic monovis lasik presbyop myopic patient monovis procedur design patient year old experienc blurri near vision due age eye estim peopl could potenti benefit monovis procedur includ improv distanc near vision johnson johnson announc accept bind offer platinum equiti acquir lifescan inc johnson johnsonannounc accept bind offer platinum equiti previous announc onmarch acquir itslifescanbusi inc world leader blood glucos monitor maker onetouch brand product juli johnson johnson| august
incom statement
non-
per share item
balanc sheet item
product perform develop
valuat consensu perform
perform
compar
gross margin ttm
compar
industri
roa roi roe
ttm basi
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit consensu view analyst trend stock
forecast expect
forward price-to-earnings
lower
jnj avgfive-year growth forecast usdgrowth high day day day estim comparisonjnjindustri avg avgprice/earn yield johnson johnson| august
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate johnson johnson| august
incom statement
non-
per share item
balanc sheet item
product perform develop
valuat consensu perform
stock price show upward momentum quarter current trade
averag volum share trade period total return given
period
stock price volatil last one year given return last one year
stock surg januari dip may
week rang stock
stock price show upward trend past huge volum trade
stock given return past
recommend hold rate tp estim adjust ep
along forward look pe deliv strong quarterli perform due
double-digit growth segment continu increas sale medic devic
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host ofclient
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com orcontact
